Use of midazolam in the treatment of refractory status epilepticus

Daniel F Hanley, John F. Kross

Research output: Contribution to journalArticle

Abstract

Status epilepticus is an epileptic seizure that lasts at least 30 minutes or is repeated at sufficiently brief intervals to produce a continued epileptic condition lasting a total of 30 minutes without the patient fully regaining consciousness. Various combinations of anticonvulsant agents, including benzodiazepines, phenytoin, and phenobarbital, have been used to manage this condition. However, at least 9% of patients with generalized convulsive status epilepticus do not respond to conventional first-line agents, and additional intervention is required. Refractory status epilepticus refers to sustained seizures that do not respond to initial drug therapy and persist longer than 60 minutes. Reports on the response to first- and second-line agents suggest that the incidence of refractory status epilepticus is between 2000 and 6000 cases per year in the United States. Refractory status epilepticus is a major medical and neurologic emergency that requires immediate treatment to avoid significant morbidity and mortality. The anticonvulsive agent midazolam has proved to be effective, well tolerated, and fast acting when used to treat refractory status epilepticus in both adults and children. Its pharmacodynamic effects can be seen within 1 to 5 minutes of administration, and its anticonvulsive effects are apparent as early as 5 to 15 minutes after administration. This article reviews the pharmacology of midazolam and recent clinical reports on the drug's tolerability and effectiveness in the treatment of patients with refractory status epilepticus.

Original languageEnglish (US)
Pages (from-to)1093-1105
Number of pages13
JournalClinical Therapeutics
Volume20
Issue number6
DOIs
StatePublished - 1998

Fingerprint

Status Epilepticus
Midazolam
Anticonvulsants
Therapeutics
Phenytoin
Phenobarbital
Consciousness
Benzodiazepines
Nervous System
Epilepsy
Seizures
Emergencies
Pharmacology
Morbidity
Drug Therapy
Mortality
Incidence
Pharmaceutical Preparations

Keywords

  • Anticonvulsives
  • Benzodiazepines
  • Midazolam
  • Phenytoin
  • Refractory status epilepticus

ASJC Scopus subject areas

  • Pharmacology

Cite this

Use of midazolam in the treatment of refractory status epilepticus. / Hanley, Daniel F; Kross, John F.

In: Clinical Therapeutics, Vol. 20, No. 6, 1998, p. 1093-1105.

Research output: Contribution to journalArticle

@article{6f4767b600cd437a825aed6a1ef38c53,
title = "Use of midazolam in the treatment of refractory status epilepticus",
abstract = "Status epilepticus is an epileptic seizure that lasts at least 30 minutes or is repeated at sufficiently brief intervals to produce a continued epileptic condition lasting a total of 30 minutes without the patient fully regaining consciousness. Various combinations of anticonvulsant agents, including benzodiazepines, phenytoin, and phenobarbital, have been used to manage this condition. However, at least 9{\%} of patients with generalized convulsive status epilepticus do not respond to conventional first-line agents, and additional intervention is required. Refractory status epilepticus refers to sustained seizures that do not respond to initial drug therapy and persist longer than 60 minutes. Reports on the response to first- and second-line agents suggest that the incidence of refractory status epilepticus is between 2000 and 6000 cases per year in the United States. Refractory status epilepticus is a major medical and neurologic emergency that requires immediate treatment to avoid significant morbidity and mortality. The anticonvulsive agent midazolam has proved to be effective, well tolerated, and fast acting when used to treat refractory status epilepticus in both adults and children. Its pharmacodynamic effects can be seen within 1 to 5 minutes of administration, and its anticonvulsive effects are apparent as early as 5 to 15 minutes after administration. This article reviews the pharmacology of midazolam and recent clinical reports on the drug's tolerability and effectiveness in the treatment of patients with refractory status epilepticus.",
keywords = "Anticonvulsives, Benzodiazepines, Midazolam, Phenytoin, Refractory status epilepticus",
author = "Hanley, {Daniel F} and Kross, {John F.}",
year = "1998",
doi = "10.1016/S0149-2918(98)80106-9",
language = "English (US)",
volume = "20",
pages = "1093--1105",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "6",

}

TY - JOUR

T1 - Use of midazolam in the treatment of refractory status epilepticus

AU - Hanley, Daniel F

AU - Kross, John F.

PY - 1998

Y1 - 1998

N2 - Status epilepticus is an epileptic seizure that lasts at least 30 minutes or is repeated at sufficiently brief intervals to produce a continued epileptic condition lasting a total of 30 minutes without the patient fully regaining consciousness. Various combinations of anticonvulsant agents, including benzodiazepines, phenytoin, and phenobarbital, have been used to manage this condition. However, at least 9% of patients with generalized convulsive status epilepticus do not respond to conventional first-line agents, and additional intervention is required. Refractory status epilepticus refers to sustained seizures that do not respond to initial drug therapy and persist longer than 60 minutes. Reports on the response to first- and second-line agents suggest that the incidence of refractory status epilepticus is between 2000 and 6000 cases per year in the United States. Refractory status epilepticus is a major medical and neurologic emergency that requires immediate treatment to avoid significant morbidity and mortality. The anticonvulsive agent midazolam has proved to be effective, well tolerated, and fast acting when used to treat refractory status epilepticus in both adults and children. Its pharmacodynamic effects can be seen within 1 to 5 minutes of administration, and its anticonvulsive effects are apparent as early as 5 to 15 minutes after administration. This article reviews the pharmacology of midazolam and recent clinical reports on the drug's tolerability and effectiveness in the treatment of patients with refractory status epilepticus.

AB - Status epilepticus is an epileptic seizure that lasts at least 30 minutes or is repeated at sufficiently brief intervals to produce a continued epileptic condition lasting a total of 30 minutes without the patient fully regaining consciousness. Various combinations of anticonvulsant agents, including benzodiazepines, phenytoin, and phenobarbital, have been used to manage this condition. However, at least 9% of patients with generalized convulsive status epilepticus do not respond to conventional first-line agents, and additional intervention is required. Refractory status epilepticus refers to sustained seizures that do not respond to initial drug therapy and persist longer than 60 minutes. Reports on the response to first- and second-line agents suggest that the incidence of refractory status epilepticus is between 2000 and 6000 cases per year in the United States. Refractory status epilepticus is a major medical and neurologic emergency that requires immediate treatment to avoid significant morbidity and mortality. The anticonvulsive agent midazolam has proved to be effective, well tolerated, and fast acting when used to treat refractory status epilepticus in both adults and children. Its pharmacodynamic effects can be seen within 1 to 5 minutes of administration, and its anticonvulsive effects are apparent as early as 5 to 15 minutes after administration. This article reviews the pharmacology of midazolam and recent clinical reports on the drug's tolerability and effectiveness in the treatment of patients with refractory status epilepticus.

KW - Anticonvulsives

KW - Benzodiazepines

KW - Midazolam

KW - Phenytoin

KW - Refractory status epilepticus

UR - http://www.scopus.com/inward/record.url?scp=0032447714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032447714&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(98)80106-9

DO - 10.1016/S0149-2918(98)80106-9

M3 - Article

C2 - 9916604

AN - SCOPUS:0032447714

VL - 20

SP - 1093

EP - 1105

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 6

ER -